Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Page 3 of 30
Oct 8, 2026The trial in 126 adults linked FB102 to statistically significant improvement in villus height–to–crypt depth versus placebo at Day 78 during an oral gluten challenge. While argenx did not disclose detailed efficacy data beyond a 0.0176 p value for the primary analysis, it said the results support phase 3 development.
Oct 8, 2026The New Albany site will serve U.S. and global markets, initially in oncology, cardiovascular disease and renal care, and is expected to support about 600 jobs plus roughly 1,500 construction roles. The project also places Bayer alongside peers that have announced major U.S. drug-production investments amid political pressure to reshore manufacturing.
Oct 7, 2026The new Cambridge building combines lab space, offices, robotics, continuous automation and agentic AI in a site designed for multiple therapeutic areas. Strategically, the move is less about a ribbon-cutting than about concentrating talent and research infrastructure inside one of biotech's densest collaboration hubs.
Oct 6, 2026Shionogi said the acquisition of privately held IntraBio will deepen its rare disease capabilities and strengthen its portfolio. The centerpiece is Aqneursa, which now has FDA approvals in Niemann-Pick disease type C and ataxia-telangiectasia, giving Shionogi a revenue-generating product rather than another earlier-stage pipeline bet.
Oct 5, 2026The agreement gives Genentech exclusive development and commercialization rights to AL050 across all indications, while Alector retains ownership of its blood-brain barrier delivery platform. For Roche’s Genentech, the transaction adds another external route into brain delivery as the company also advances its own Brainshuttle work.
Oct 5, 2026Australia’s CSL is taking rights to co-develop and co-commercialize Alentis Therapeutics’ phase 2-stage anti-Claudin-1 drug lixudebart. Beyond the upfront payment, CSL will fund ongoing and planned studies and split overall profits 55% to 45% in its favor, turning the partnership into both a licensing deal and a franchise-building move in nephrology.
Oct 5, 2026Roivant Sciences is trying to prove it can do more than acquire and develop overlooked assets through subsidiaries. With Priovant’s Lisraya approved and two other major programs advancing, the company is testing whether its model can support durable commercial performance after a mixed experience with Vtama.
Oct 2, 2026Pfizer’s once-daily JAK3/TEC inhibitor Litfulo met key Phase 3 measures in nonsegmental vitiligo after 52 weeks, with higher response rates than placebo on both facial and total-body repigmentation endpoints. The result opens a potential label expansion beyond alopecia areata and gives Pfizer an entry into a market where Incyte already has the only FDA-approved vitiligo drug and AbbVie has added a European label for Rinvoq.
Oct 2, 2026The agreement gives Novartis global rights to ABO2203 and an exclusive option to license a certain number of next-generation assets from Abogen’s RNA platform. It also adds another China-originated program to Novartis’ business development slate, this time around an mRNA approach that Abogen says may mitigate cytokine release syndrome associated with T cell engagers.
Oct 1, 2026The renewed alliance gives Sanofi access to a slate led by Phase 1 candidate REGN20423, plus three preclinical programs expected to enter human studies next year. It also settles recent litigation between the companies and creates a mechanism for Regeneron to opt lunsekimig into the collaboration after Phase 3 chronic obstructive pulmonary disease data.
Oct 1, 2026The company said it plans to start phase 3 trials in the fourth quarter of 2026 based on results presented at the European Association for the Study of Diabetes meeting. The data also sharpen the commercial case for amylin combinations, while leaving tolerability and discontinuation rates as a key development question.
Oct 1, 2026The newly detailed phase 2 dataset suggests petrelintide may have reached its efficacy ceiling at a middle dose rather than through continued escalation. That sharpens the strategic case Roche and Zealand are making: compete on tolerability and positioning, not on top-line weight loss leadership within the amylin class.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.